Telix Pharmaceuticals Limited has announced the dosing of the first patient in its Phase III ProstACT GLOBAL study, evaluating TLX591, an antibody-based prostate cancer therapy candidate. This marks a significant milestone for Telix as it advances the development of this potential first-in-class radioantibody-drug conjugate (rADC). The trial aims to assess the efficacy and safety of TLX591 in a large patient population, potentially offering a new treatment option for individuals with prostate cancer.
The ProstACT GLOBAL study is designed to build upon the existing data set for TLX591. The current TLX591 experience underlines the potential benefits of an antibody-based approach in combination with real world standards of care, including physician choice of ARPI or taxane.
Dr. Colin Hayward, Group Chief Medical Officer of Telix, stated, "Dosing a first patient in the ProstACT GLOBAL study is a significant milestone for Telix and will help build on an already extensive data set for this product candidate."
TLX591 represents a novel approach to prostate cancer treatment by combining the specificity of an antibody with the therapeutic effect of a radioisotope. This targeted delivery aims to minimize off-target effects and maximize the impact on cancer cells. The Phase III trial will further evaluate the potential of TLX591 to improve outcomes for patients with prostate cancer.
